Close

BioCryst (BCRX) Receives Prelim. Comment Letter from FDA for Peramivir

April 1, 2013 6:20 AM EDT Send to a Friend
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it received
a preliminary comment letter from the U.S. Food & Drug Administration ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login